JIM
BMRN icon

Jupiter Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jupiter Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6,151
Closed -$520K – 378
2019
Q4 		$520K Sell
6,151
-18,830
-75% -$1.42M 0.01% 358
2019
Q3 		$1.68M Buy
+24,981
New +$1.92M 0.02% 318
2016
Q1 		– Sell
-6,590
Closed -$690K – 470
2015
Q4 		$690K Buy
+6,590
New +$688K 0.02% 197

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jupiter Investment Management's BMRN Position: Q1 2020 in Review

Jupiter Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2020, closing a stake of 6,151 shares — an estimated $520K sold.

Jupiter Investment Management first reported a position in BMRN in Q4 2015 and held it in 3 quarters. The position peaked at $1.68M in Q3 2019. 500 funds tracked by Wall St. Rank hold BMRN as of Q1 2020.

  • Jupiter Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Jupiter Investment Management sold 6,151 BioMarin Pharmaceuticals shares in Q1 2020, an estimated $520K.
  • Jupiter Investment Management first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 3 quarters.
  • Jupiter Investment Management's BioMarin Pharmaceuticals position peaked at $1.68M in Q3 2019.
  • 500 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2020.

Based on Jupiter Investment Management's 13F filing for Q1 2020, filed 23 Apr 2020.